WCM Investment Management LLC Cuts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

WCM Investment Management LLC cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 284,622 shares of the biopharmaceutical company’s stock after selling 15,423 shares during the quarter. WCM Investment Management LLC owned approximately 0.22% of Halozyme Therapeutics worth $13,659,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Advisors Preferred LLC acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $2,024,000. Financial Advocates Investment Management acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $478,000. State of Alaska Department of Revenue raised its stake in Halozyme Therapeutics by 213.4% in the 4th quarter. State of Alaska Department of Revenue now owns 46,508 shares of the biopharmaceutical company’s stock valued at $2,222,000 after purchasing an additional 31,670 shares during the last quarter. Verity Asset Management Inc. lifted its holdings in Halozyme Therapeutics by 19.3% in the 4th quarter. Verity Asset Management Inc. now owns 45,616 shares of the biopharmaceutical company’s stock valued at $2,181,000 after purchasing an additional 7,368 shares in the last quarter. Finally, Tempus Wealth Planning LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter worth $265,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HALO. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Finally, JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Down 1.4 %

Shares of NASDAQ:HALO opened at $57.10 on Monday. The company has a market capitalization of $7.26 billion, a price-to-earnings ratio of 18.91, a PEG ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 12-month low of $34.36 and a 12-month high of $65.53. The business has a 50-day moving average price of $51.55 and a 200 day moving average price of $54.41. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.